Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Subscribe To Our Newsletter & Stay Updated